Drugs for Heart Failure Flashcards

1
Q

Principal symptoms of HF

A

Dyspnea and fatigue
Exercise intolerance
Fluid retention
Some present primarily with exercise intolerance, others fluid overload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

People w/ HTN have a ___ increased risk of HF

A

6x

need to manage HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Several complex compensatory mechanisms to maintain cardiac output and oxygenation of vital organs

(4)

A

Increased sympathetic tone
Activation of renin-angiotensin-aldosterone system: Sodium and water retention

Cardiac remodeling (ventricular dilation and hypertrophy)
(we don't have meds that affect this)

Other neurohormonal adaptations – endothelial hormones, vasopressin, natriuretic peptide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sympathetic Autonomic Nervous System as it pertains to HF

A

Initially NE causes increased inotropic and chronotropic effects –> maintain near-normal CO and preserve perfusion of vital organs (CNS, heart)

Vasoconstriction in skin, GI, renal circulation decreases perfusion to these organs, and increases cardiac work load via –> SVR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

in response to NE

beta1 receptors-G protein effector system ____ and with
beta 2 _______

A

beta1 receptors-G protein effector system downregulation

beta 2 not affected

this is why we give BB even though we see a further decrease in HR initially

but if we block the beta receptor you can re-sensitize the body to the NE that is there

w/ first dose sxs can worsen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ANP is the bodies

A

natural diuretic

Released from specialized cells in atrial (ANP) or ventricular (BNP) muscle in response to stretching of myocytes
Results in direct arterial vasodilation, increased GFR, and diuresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Low output failure

A

diminished volume of blood pumped by a weakened heart in patients who have otherwise normal metabolic needs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

High output failure

A

high metabolic demands due to underlying medical conditions (hyperthyroidism, anemia) –>healthy heart, pumps normal to high volume of blood; –> heart becomes exhausted fromincrease work load and unable to meet demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

High output failure tx

A

need to tx underlying condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
Ejection fraction (EF) < 40%
Reduced myocardial muscle contractility
Enlarged heart (dilated left ventricle)
A

HFrEF – systolic heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Normal EF (>50%), decrease SV & CO
Normal left ventricular contractility
Stiff left ventricle with impaired left ventricular filling

A

HFpEF – diastolic heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Heart Failure Etiology

A

Hypertension  Valvular disease
Amyloidosis, sarcoidosis Coronary ischemia
Pericarditis
Drug Induced
Alcoholism Scarring post-MI
Enlarged left ventricular septum (hypertrophic cardiomyopathy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Symptoms of heart failure

A
SOB
Cough
Orthopnea
PND (paroxysmal nocturnal dyspnea)
DOE (dyspnea on exertion)
Reduced exercise tolerance
Fatigue
Weight gain
Edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Physical findings in HF

A
Tachycardia
Increasing weight
JVD or hepatojugular reflex
Presence of S3
Laterally displaced apical impulse
Fluid retention 
        Pulmonary crackles or 
        wheezes
        Peripheral edema
Hepatomegaly
Objective test to measure EF (2-D echocardiogram with Doppler flow studies or cardiac catheterization)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Non-pharmacologic Interventions To reduce risk of new cardiac injury

A

Attain or maintain normal weight
Smoking cessation
Alcohol consumption discouraged
Manage co-morbities (HTN, DM, HLP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Interventions To reduce risk of new cardiac injury Maintain fluid balance

A

Na restriction, daily weight, fluid restriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is structural heart dz (stage B)

A

vascular dz
remodeling
valve issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

stage A of heart failure

A

pts without strucutral heart diease but with

htn
dm
atherosclerotic dz
obesity
metabolic syndrome 

or using cardiotoxins or with Fhx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

1st line TX for HF

A

ACEI and BB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

staging A B C D of HF

A

doesn’t move back and forth

A. no structural abnormalities but high risk
B structural disease but without sxs
C. structural disease with prior sxs
D, refractory HF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

RAAS drugs

A

ACE and ARB
BB
not CCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Diuretics provide what kind of control in HF

A

sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

two kinds of K sparing diuretics

A

aldosterone antagonists: spironalactonin and eplerenone

inhibitions of Na/k pump: triamterene and amiloride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

two types of aldosterone antagonists

A

spironlactone and

eplerenone has less hormonal effects and is more specific for receptors in the kidney and less overall steroid effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

which diuretics are used in HF

A

loop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

how often do you dose loop diuretics in HF

A

once a day

2x daily for HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what labs do you want to monitor on a loop

A

K

creatinin to monitor their renal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

why do we worry about kidney function in loop diuretics?

A

decreased renal profusion through hypotension and decreased renal sufficiency

don’t want too dramatic of a diuresis
takes a while for interstitial fluid to redistribute back into the blood stream

Hypokalemic metabolic acidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

name the loop diuretics (4)

which one can be used with a sulfa allergy

A
Furosemide
Bumetanide
Torsemide
Ethacrynic acid
"	--->Only one that can be used w/ sulfa allergy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

why do we loose Mg with loops

A

normally you get excess K seeping back into the tubule net positive charge results in the absorption of Ca and Mg

if you’re blocking this you loose Mg

wut? look into this later

31
Q

what is the mechanism (if you have renal artery stenosis ) by which you will see renal failure with ARB and ACEI

A

blocking angiotensin and dialating efferent

you are blocking efferent
but if you have stenosis in the afferent arteriole

won’t have as much back pressure and wont’ have sufficient filtration

will lead to a dramatic rise in creatinine

32
Q

what do we need to monitor in a pt taking ARB

A

” Monitor BP, renal fxn, for hyperkalemia since increase serum Cr and worsen renal function w/in 1-2 wks

33
Q

ACEI names and dosages

A

Benazapril

Captopril
-6.25- 12.5mg tid

Enalapril
-2.5-5mg qd (20mg)

Fosinopril
-5-10mg qd (20mg)

Lisinopril
-2.5-5mg (20mg)

Moexipril

34
Q

name ARBS

A
Candesartan
-8-32mg qd
Irbesartan
-75-300mg qd
Losartan
-25-100mg qd
Telmisartan
Valsartan
-80-320mg qd
Azilasartan
35
Q

Mechanism by which loop diuretics work that interferes with NSAIDS

A

giving a non steroidal blocks the production of prostaglandins through the COX pathway and negates HTN effect

36
Q

angioedema with ACEI is there cross reactivity with ARBs?

A

no, it looks like you should wait 6 weeks after stopping the ACEI though

37
Q

3 BB for cardio protection

A

Metoprolol XL
Carvedilol
Bisoprolol

38
Q

Sacubitril and Valsartran (Entresto)

indication

A

patients with optimal dosing ACE/ARB and beta-blockers and MRA

CI with ACEI

39
Q

MOA w/ BB in HF

A

Deactivation of SNS –> leads to B-receptor down-regulation, LVH, arrhythmia, cardiotoxic effects

they reduce mortality AS LONG AS they are dose appropriately

40
Q

which BB for HF is non selective and is associated with alpha adrenergic blocking and antioxidant effects

A

carvedilol (coreg)

41
Q

If pt has borderline BP and HF which BB would you be most likely to use

A

alpha blocking gives you unopposed beta 2
alpha blocking is vasodialating

metroprolol is more selective and is usually used in pts with lower blood pressure

however as long as you use appropriate dosing you could in theory use both

42
Q

Metoprolol XL initial dosing for HF

and target

A

12.5-25mg 1xday

most people are 25 2x daily

43
Q

Carvedilol (Coreg, generiic) initial dosing for HF

and target

A

initial dose 3.125mg bid, titrate at minimum q2 wks to target 25 – 50 mg bid

people will often see worsening of HF sxs initially because of up regulation initially

44
Q

Bisoprolol (Zebeta) initial dosing for HF

and target

A

not used as frequently as carved or meto

initial dose 1.25mg qd; increase by 1.25mg q wk until 5mg qd, then increase by 2.5mg q4 wks to target dose 10mg qd

45
Q

why do we give carvedilol with food?

A

Carvedilol should be given with food to reduce incidence of orthostatic hypotension

46
Q

why should you not abruptly stop a BB

A

because you would have sns surge (rebound)

47
Q

Ivabradine (Corlanor) MOA

A

slow heart rate through a different mechanism than bb

: inhibits f-channels in the SA node, prolonging diastole, reducing heart rate

48
Q

Ivabradine (Corlanor) indicated for pts who…

A

on target dose of BB but still have HR over 77

49
Q

BiDil is a combination of what two drugs

A

combination hydralazine 37.5mg (vasodilator) and isosorbide dinitrate 20mg

50
Q

when is BiDil indicated

A

shown to further reduce mortality in AA population

51
Q

hydralazine reduces….

ISDN reduces…..

MOA of BiDil

A

” Vasodilator
“ Mixed

Hydralazine: ↓afterload

ISDN: ↓preload

similar to an ACE because it addresses both

52
Q

how do ACEI reduce preload and afterload

A

reduce vasoconstriction (afterload) and release of aldosterone (preload)

53
Q

MOA of digoxin

A

Blocks Na-K-ATPase pump and therefore Na-Ca exchanger –>

↑Ca (intracellular) —> ↑contractility and have positive anotropic effect

54
Q

two effects of digoxin

A

direct on AP duration

and PSNS effects (slower)

can block conduction in supraventricular arrhythmias

55
Q

why does digoxin not reduce mortality? what is it doing?

A

does not actually save lives because of pro arrhythmic effect

just decreases sxs and hospitalizations

56
Q

indications of digoxin

A

in stage III on pts already on ACEI and BB to minimize hospitalizations

maybe for afib too

57
Q

1/2 life of digoxin

A

1.5-2 days

x 4-5 to get to a steady state
= week to a week and a half

58
Q

ADE of digoxin

A

” AV block /arrhythmias (Prolonged PR interval)
“ —>Junctional rhythms, MAT w/ block, PAT, AF, PVCs,
VT, VF

” High risk hypokalemia

we see hypokalemia though with diuretics so this is an issue…

59
Q

hallmark of digoxin toxicity

A

visual disturbances and halos around lights

60
Q

digoxin levels at trough

A

.5-.9 ng/ml

make sure this is NOT during post distribution phase
have pt withhold meds in morning if you are running dig levels

takes 4 hours to distribute with IV
6-8 hours with PO

61
Q

besides AV blocks and arrhythmias what side effects are we looking for that indicate toxicity

A

” Anorexia, N/D
“ Gynecomastia in chronic therapy
“ CNS: fatigue, weakness, psychic & visual disturbances (hazy, yellow-green vision)

62
Q

digitilization

A

give loading dose over 24 hr period to allow time for distribution

63
Q

what are we concerned about in a pt on Erythromycin or tetracyclines

A

knocks out bacteria in the gut and decreases absorbtion

64
Q

DID with digoxin

A

Antacids, cholestyramine, colestipol, kaolin-pectin: reduced absorption due to adsorption

Erythromycin, tetracyclines
Erythromycin, tetracyclines
Laxatives, metoclopramide: reduced absorption due to increased gut motility

65
Q

what can we do for a pt with an arrhythmia who we suspect has a dig overdose

A

Digibind

66
Q

Drugs for Acutely Decompensated HF

A

Diuretics: loop +/- HCTZ or metolazone
metaolzaone
o Vasodilator: Nitroprusside or nitrate. Used in fluid overload to decrease preload
o Inotropes stimulate contraction; only used in people w/ low BP

67
Q

why do we use Diuretics: loop +/- HCTZ in Acutely Decompensated HF

A

blocks sequential parts of the loop and dramatically increases diuresis

68
Q

Nitroprusside

A

only given IV
potent vasodilator; activates guanyl cyclace leads to increase cGMP –> smooth muscle relaxation
Dilates both venous and arterial vessels – reduces preload and afterload

2 minute half life

used in immediate short term for rapid bp control
has both preload and afterload reduction for the mngmt of HF

69
Q

Milrinone

A

only used short term for decomp in HF awaiting heart transplant
Both inotropic and vasodilating
Selectively inhibit phosphodiesterase F –III (cardiac and vascular cyclic-AMP-specific)   cAMP  Ca++ flux  enhanced contractility

only used short term because it causes arrhythmias

70
Q

b1-selective synthetic catecholamine which also activates b1 receptors
Increased myocardial contractility, HR and CO, but also increases myocardial oxygen demand
Given as long term infusion for 48-72 hours in patients with refractory HF or awaiting transplant

A

Dobutamine

71
Q

Immediate metabolic precursor of NE
Activates D1 receptors in several vascular beds –> vasodilation (effect on renal vasculature may be of clinical importance; better than dobutamine); also activates B 1 receptors in heart

A

Dopamine

72
Q

Drugs that INDUCE heart failure:

A

Negative inotropic drugs: BB, CCB, antiarrhythmics (disopyramide, quinidine)

Direct cardiotoxins: cocaine, amphetamines, anthracyclines (doxorubicin, daunorubicin)

Anti-TNF agents: etanercept, infliximab

Drugs that cause plasma volume expansion: NSAIDs, glucocorticoids, estrogens, androgens, black licorice, antihypertensive vasodilators (hydralazine, methyldopa, prazosin, minoxidil –> decrease RBF and activate RAAS), drugs high in Na

73
Q

Drugs that cause plasma volume expansion

A

NSAIDs, glucocorticoids, estrogens, androgens, black licorice, antihypertensive vasodilators (hydralazine, methyldopa, prazosin, minoxidil –> decrease RBF and activate RAAS), drugs high in Na